Virologic Outcomes With Lenacapavir in People With Human Immunodeficiency Virus: A Multicenter Real-World Study

Open Forum Infectious Diseases 2026 Open access

Read full text
Authors: Christopher J. Kaperak, Yijia Li, Beverly E. Sha, Mônica Merçon, Karen Montes, Fatima Sanes, Shivanjali Shankaran, Mariam Aziz, Catherine Creticos, Nancy R. Glick, Bijou R. Hunt, Sharon Sam
+3 more Paul S Djuricich, Andrew Merker, Aniruddha Hazra
DOI: 10.1093/ofid/ofag425
Cited by: 1
References: 20

Abstract

Abstract Background Lenacapavir (LEN), a first-in-class long-acting human immunodeficiency virus type 1 (HIV-1) capsid inhibitor, has demonstrated potent antiviral activity in heavily treatment-experienced (HTE) people with HIV (PWH) in clinical trials, but real-world data remain limited. We describe outcomes from 6 US HIV clinics using LEN-based regimens in a largely HTE cohort of PWH to assess virologic response, regimen potency, and tolerability. Methods We conducted a multicenter retrospective cohort study of adults with HIV who initiated LEN between November 2020 and June 2025 at 6 clinics in Chicago, Illinois and Pittsburgh, Pennsylvania. Demographic, clinical, and genotypic data were abstracted from electronic health records. Virologic suppression was defined as HIV viral load

Fields of Study & Subjects

HIV/AIDS drug development and treatment HIV Research and Treatment HIV/AIDS Research and Interventions

Publication details

Journal / source
Open Forum Infectious Diseases
Publisher
Oxford University Press (OUP)
Volume
13
Issue
7
Pages
ofag425–ofag425
Publication date
1 July 2026
Language
EN